Aardvark Therapeutics (AARD) Return on Capital Employed (2025 - 2026)
Aardvark Therapeutics (AARD) reported Return on Capital Employed of 77.6% for Q1 2026, down 4967.0% on a YoY basis from 1.59% in Q1 2025, and down 41.86% sequentially from 54.71% in Q4 2025.
Aardvark Therapeutics (AARD) Return on Capital Employed (2025 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 2 years of Return on Capital Employed data on file, last reported at 77.6% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 4967.0% year-over-year to 77.6%; the trailing twelve-month figure through Mar 2026 stood at 77.6% (down 4967.0% YoY), and the FY2025 full-year result was 72.27%, changed N/A from the prior year.
- Return on Capital Employed retreated to 77.6% in Q1 2026, from 54.71% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 27.93% in Q1 2025 to a low of 77.6% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | -77.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.60% |
| Dec 31, 2025 | -54.71% |
| Sep 30, 2025 | -41.25% |
| Jun 30, 2025 | -28.79% |
| Mar 31, 2025 | -27.93% |